Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for sn-38, an active metabolite of irinotecan, in humans

Pharmaceutical Research

Volumn 31, Issue 1, 2014, Pages 204-215

  Fujita, Ken Ichi ^a   Sugiura, Tomoko ^b   Okumura, Hidenori ^b   Umeda, Saki ^b   Nakamichi, Noritaka ^b   Watanabe, Yusuke ^a   Suzuki, Hiromichi ^a   Sunakawa, Yu ^a   Shimada, Ken ^a   Kawara, Kaori ^a   Sasaki, Yasutsuna ^a   Kato, Yukio ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

human hepatocytes; organic anion transporting polypeptide; renal failure; SN 38; uremic toxins

Indexed keywords

3 CARBOXY 4 METHYL 5 PROPYL 2 FURANPROPIONATE; FIRTECAN; HIPPURIC ACID; INDICAN; INDOLEACETIC ACID; MESSENGER RNA; UNCLASSIFIED DRUG; UREMIC TOXIN;

ADULT; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG TRANSPORT; FEMALE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KINETICS; LIVER CELL; MIDDLE AGED; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT;

ADULT; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE; DOWN-REGULATION; FEMALE; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS;

EID: 84891634765     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1153-x     Document Type: Article

References (25)

1. Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 1997;57(10):1934-8. (Pubitemid 27209724)
2. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998;58(22):5137-43. (Pubitemid 28521174)
3. Nakatomi K, Yoshikawa M, Oka M, Ikegami Y, Hayasaka S, Sano K, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001;288(4):827-32. (Pubitemid 33140956)
4. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33(3):434-9. (Pubitemid 40279945)
5. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, et al. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008;260(1-2):163-9.
6. Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, et al. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos. 2011;39(2):161-4.
7. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P, Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res. 2000;6(9):3451-8.
8. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898-903. (Pubitemid 351704931)
9. Reyes M, Benet LZ. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011;100(9):3831-42.
10. Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, et al. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. Drug Metab Dispos. 2010;38(10):1665-72.
11. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 2006;97(11):1255-9. (Pubitemid 44430653)
12. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn. 1981;4(11):879-85. (Pubitemid 12174128)
13. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. European Uremic Toxin Work G. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934-43. (Pubitemid 36513344)
14. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311(1):139-46. (Pubitemid 39287793)
15. De Bruyn T, Ye ZW, Peeters A, Sahi J, Baes M, Augustijns PF, et al. Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011;43(4):297-307.
16. de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther. 2008;84(2):254-62.
17. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36(10):2014-23.
18. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther. 2009;86(5):475-9.
19. Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, Wetzels JF, et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One. 2011;6(4):e18438.
20. Noe J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35(8):1308-14. (Pubitemid 47121771)
21. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001;18(9):1262-9. (Pubitemid 32846318)
22. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004;65(1):162-74. (Pubitemid 38037501)
23. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513-22. (Pubitemid 41017600)
24. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer. 2008;59(1):69-75.
25. Takane H, Kawamoto K, Sasaki T, Moriki K, Kitano H, Higuchi S, et al. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 2009;63(6):1165-9.